July 20, 2012 10:44 am by Deanna
Pogorelc | An immunotechnology startup that moved that across the Ohio-Indiana
state line in 2009 is having a big 2012 as it completes a licensing agreement
with Merck KGaA and prepares to being clinical trials of a treatment for human
papilloma virus-related cancers. PDS Biotechnology Corp. is developing its
immunotherapy technology, Versamune, as a platform for prevention and treatment
of cancers including melanoma and those caused by HPV, including cervical, head
and neck and anal cancers. Last week, PDS announced it signed a licensing deal
with Merck KGaA for use of its nanotechnology platform in two of the German
pharmaceutical company’s investigational new cancer treatments. PDS will
receive an undisclosed upfront payment in cash plus milestone payments and
royalties. CEO Dr. Frank Bedu-Addo did not respond to a request for comment but
said in a statement that the deal is “important since the company’s business
strategy is focused on a few strategic out-licensing or partnering deals at a
preclinical or early clinical stage.” According to the company’s website, it’s also
preparing to begin clinical trials this year of its lead candidate, a vaccine
for HPV-induced cancers. The Versamune platform uses positively charged,
lipid-based nanoparticles to activate dendritic cells and induce production of
critical proteins that cause T-cells to activate and proliferate, while also
reducing the population of immune-suppressive cells. In pre-clinical models in
which it was combined with other cancer-associated molecules, the platform
demonstrated improved tumor regression rates. In addition to HPV-related
cancers, the technology is also being applied in pre-clinical work toward a
melanoma vaccine and an influenza vaccine. HPV is the most common sexually
transmitted infection in the U.S.
and is the cause of nearly all cervical cancers. The FDA has approved two
preventive vaccines for HPV’ Merck’s Gardasil and GlaxoSmithKline’s Cervarix ’
but no therapeutic vaccines. Numerous companies and research institutions are
working toward one, though, including Advaxis (ADXS), which has an immunotherapy
in phase II trials, and Inovio (NYSE AMEX:INO) and Genticel, which are in
pre-clinical development. Formerly based in Cincinnati ,
PDS was lured across the state line to Lawrenceburg ,
Indiana , with a $2 million grant
from the 21st Century Research and Technology fund in 2009. Since then, it has
received a $1.3 million grant from the National Cancer Institute to file an IND for its HPV cancer
therapy and a third equity investment from lead investor Asklepios Capital.
No comments:
Post a Comment